Devizzi L, Santoro A, Bonfante V, Viviani S, Bonadonna G
Division of Medical Oncology, Istituto Nazionale Tumori, Milan, Italy.
Leuk Lymphoma. 1996 Aug;22(5-6):409-14. doi: 10.3109/10428199609054778.
Vinorelbine is a new semisynthetic vinca alkaloid that differs chemically from vinblastine by a substitution of the catharanthine moiety. The powerful cytostatic activity of vinorelbine against murine tumors, human malignant cell lines and human tumor xenografts in nude mice has been demonstrated. Phase I-II studies of intravenous vinorelbine, administered weekly as single agent or in combination chemotherapy have been conducted since 1986. Results suggest that vinorelbine has high activity in non-small cell lung cancer, breast cancer and cisplatin-resistant ovarian cancer with mild toxicity, being neutropenia the major treatment related complication. In this paper we critically review the activity of vinorelbine in pretreated Hodgkin's patients. Available results strongly suggest the inclusion of this drug in first or second line chemotherapy regimens in Hodgkin's disease.
长春瑞滨是一种新型半合成长春花生物碱，其化学结构与长春碱的不同之处在于长春质碱部分的取代。已证实长春瑞滨对小鼠肿瘤、人恶性细胞系及裸鼠人肿瘤异种移植具有强大的细胞抑制活性。自1986年以来，已开展了静脉注射长春瑞滨的I-II期研究，该药每周给药一次，可作为单一药物或联合化疗用药。结果表明，长春瑞滨在非小细胞肺癌、乳腺癌和顺铂耐药的卵巢癌中具有高活性，且毒性轻微，主要治疗相关并发症为中性粒细胞减少。在本文中，我们对长春瑞滨在经预处理的霍奇金病患者中的活性进行了批判性综述。现有结果强烈提示，该药可纳入霍奇金病一线或二线化疗方案。
